Oct 12, 2023 / 12:30PM GMT
Andrew Tsai - Jefferies - Analyst
Hi, everyone. I'm Andrew Tsai, senior biotech analyst here at Jefferies. Thanks for joining us. And for this session, we have the Athira team. Mark Litton, to my right, CEO, President; and to his right, Andrew Gengos, CFO.
Welcome both of you.
Mark Litton - Athira Pharma Inc - President&CEO
Thank you for having us.
Questions and Answers:
Andrew Tsai - Jefferies - AnalystSo maybe, we'll spend a brief couple of minutes talking about the Athira story. So for those in the audience who are less familiar, maybe talk about what you're working on, what your lead asset is, and what kind of milestones can we look forward to in the next couple of months?
Mark Litton - Athira Pharma Inc - President&CEO
Sure, sure. And thank you for having us. So Athira is a late-stage clinical biotech company. We're completely focused on neurodegeneration, and we're taking sort of a novel approach where we're using a natural repair mechanism --
Trustpilot
